Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Non-Current Assets (2017 - 2025)

Puma Biotechnology's Non-Current Assets history spans 9 years, with the latest figure at $53.6 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 18.36% year-over-year to $53.6 million; the TTM value through Dec 2025 reached $234.9 million, down 12.34%, while the annual FY2025 figure was $53.6 million, 18.36% down from the prior year.
  • Non-Current Assets reached $53.6 million in Q4 2025 per PBYI's latest filing, down from $59.3 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $94.9 million in Q1 2021 to a low of $53.6 million in Q4 2025.
  • Average Non-Current Assets over 5 years is $75.6 million, with a median of $77.3 million recorded in 2022.
  • Peak YoY movement for Non-Current Assets: soared 41.95% in 2021, then decreased 18.36% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $86.6 million in 2021, then increased by 1.4% to $87.8 million in 2022, then fell by 15.31% to $74.3 million in 2023, then decreased by 11.66% to $65.7 million in 2024, then fell by 18.36% to $53.6 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Non-Current Assets are $53.6 million (Q4 2025), $59.3 million (Q3 2025), and $58.3 million (Q2 2025).